Generic Tiotropium bromide 18 µg DPI, developed by Phargentis, receives approval in 28 European countries
(November 11, 2021) Tiotropium bromide 18 µg Dry Powder Inhaler is the first generic product approved in the EU with the same strength and same delivered dose as Spiriva®Handihaler®, the global first line treatment for COPD – enabling possibility for full reimbursement across the European Union and other key international markets. Developed by Phargentis, it has now been approved in 28 European Countries. Global turnover for Spiriva®Handihaler® in 2020 exceeded 2.5 bUSD (IQVIA).Phargentis, an agile, small-scale pharmaceutical company headquartered in Switzerland, has earned the approval of